Lentris 4mg Capsule contains Lenvatinib, a multi-targeted tyrosine kinase inhibitor indicated for the treatment of certain types of cancer, including differentiated thyroid cancer, hepatocellular carcinoma, and advanced renal cell carcinoma. Lenvatinib exerts its therapeutic effect by inhibiting multiple receptor tyrosine kinases involved in tumor angiogenesis and proliferation, such as vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), platelet-derived growth factor receptor alpha (PDGFRα), RET, and KIT. This inhibition disrupts tumor blood supply and growth signaling pathways, thereby reducing tumor progression. Lentris 4mg Capsule is administered orally, with dosage and treatment duration determined by the prescribing physician based on the specific cancer type, patient response, and tolerability. Common adverse effects include hypertension, fatigue, diarrhea, decreased appetite, and proteinuria, necessitating regular monitoring of blood pressure, renal function, and liver enzymes during therapy. Dose adjustments or temporary discontinuation may be required in the event of severe toxicity. Lentris should be used under strict medical supervision, considering potential drug interactions and contraindications. It is contraindicated in pregnancy due to teratogenic risks. Patients are advised to report any unusual symptoms promptly to ensure safe and effective treatment outcomes.